Uterine Arteriovenous Malformation - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Uterine Arteriovenous Malformation – Comprehensive Guide

Overview

A uterine arteriovenous malformation (UAVM) is an abnormal, direct connection between arteries and veins in the uterus that bypasses the normal capillary network. These tangles of vessels create a high‑flow lesion that can bleed heavily when disturbed. UAVMs are rare but potentially life‑threatening, primarily because they can cause profuse uterine bleeding.

Who it affects: UAVMs most commonly appear in women of reproductive age, especially those between 20 and 40 years, but cases have been reported from adolescence through menopause. Although both congenital (present at birth) and acquired forms exist, the acquired type accounts for > 80 % of diagnosed cases.1

Prevalence: Exact epidemiologic data are limited due to under‑recognition. Estimates suggest that UAVMs represent less than 0.1 % of all cases of abnormal uterine bleeding, with roughly 1–2 cases per 100,000 women per year.2 Awareness is growing as Doppler ultrasound becomes more widely used.

Symptoms

Symptoms result from the high‑flow vascular network and can range from mild to catastrophic. Common presentations include:

  • Heavy or prolonged menstrual bleeding (menorrhagia): Bleeding that soaks more than one pad per hour or lasts longer than 7 days.
  • Intermenstrual (breakthrough) bleeding: Spotting or bleeding between periods, often sudden.
  • Painless vaginal bleeding after pregnancy‑related events: After dilation & curettage (D&C), miscarriage, or delivery.
  • Post‑procedural hemorrhage: Bleeding that begins 24–72 hours after hysteroscopic, laparoscopic, or obstetric procedures.
  • Pelvic pain or pressure: Usually mild, but can be severe if the lesion expands.
  • Anemia symptoms: Fatigue, shortness of breath, dizziness due to chronic blood loss.
  • Shock: In rare, massive bleeds (≥ 1 L loss) the patient may develop rapid pulse, low blood pressure, and pale skin.

Because the bleeding is arterial, it may be bright red and spurting rather than the typical dark clotted flow of venous bleeding.

Causes and Risk Factors

UAVMs are classified as either congenital or acquired.

Congenital UAVM

  • Result from embryologic errors when the primitive vascular plexus fails to differentiate into normal capillaries.
  • Often associated with other vascular anomalies, such as hereditary hemorrhagic telangiectasia (Osler‑Weber‑Rendu disease).

Acquired UAVM

Accounts for the majority of cases and is usually linked to uterine trauma or hormonal influences:

  • Procedural trauma: Dilation & curettage, hysteroscopic polypectomy, myomectomy, cesarean section, or uterine artery embolization (UAE) itself.
  • Pregnancy‑related events: Miscarriage, termination, or retained products of conception.
  • Uterine tumors: Large fibroids (leiomyomas) or gestational trophoblastic disease can erode into vessels.
  • Hormonal factors: High estrogen states may promote angiogenesis, making vessels more prone to malformation.

Risk Factors

  • History of uterine surgery or instrumentation.
  • Prior abortions (spontaneous or induced) or D&C procedures.
  • Multiparity (having given birth multiple times).
  • Underlying vascular disease (e.g., hereditary hemorrhagic telangiectasia).
  • Use of high‑dose estrogen therapy or fertility drugs.

Diagnosis

Because UAVM mimics other causes of abnormal uterine bleeding (e.g., fibroids, polyps, malignancy), a systematic approach is essential.

Clinical Assessment

  • Detailed menstrual and procedural history.
  • Physical exam focusing on hemodynamic status (pulse, blood pressure).
  • Speculum exam to evaluate active bleeding.

Imaging Studies

  1. Transvaginal Color Doppler Ultrasound (TV‑CDUS): First‑line test. Shows a heterogeneous, hypoechoic lesion with turbulent, high‑velocity (≥ 30 cm/s) arterial flow and low‑resistance indices (< 0.5).3
  2. Three‑Dimensional (3‑D) Power Doppler: Improves visualization of the vascular architecture and helps differentiate UAVM from fibroids.
  3. Magnetic Resonance Imaging (MRI) with contrast: Provides detailed anatomic mapping, especially useful before surgery or embolization.
  4. CT Angiography: Reserved for unstable patients when rapid vessel localization is needed.
  5. Conventional Pelvic Angiography: Gold standard for definitive diagnosis and simultaneously offers therapeutic embolization. Shows early venous filling and a “nidus” of vessels.

Laboratory Tests

  • Complete blood count (CBC) – to assess anemia.
  • Serum β‑hCG – to rule out persistent trophoblastic tissue.
  • Coagulation profile – especially if planning an invasive procedure.

Treatment Options

Management is individualized based on severity of bleeding, desire for future fertility, and overall health.

Conservative / Medical Management

  • Tranexamic acid: Antifibrinolytic that can reduce acute bleeding but does not treat the lesion.
  • Hormonal therapy: High‑dose progestins or GnRH agonists may temporarily shrink the vascular bed, but evidence is limited.
  • Iron supplementation: Oral or intravenous iron to correct anemia.
  • Medical options are generally adjunctive; they rarely eradicate the malformation.

Minimally Invasive Procedures

  1. Uterine Artery Embolization (UAE): Interventional radiology technique where tiny particles are injected to block the feeding arteries. Success rates 80‑95 % with preservation of the uterus in most cases.4 Risks include post‑embolization syndrome (pain, fever) and rare uterine necrosis.
  2. Hysteroscopic Resection: Direct visualization and excision of a superficial UAVM. Suitable only for small, localized lesions and when fertility preservation is a priority.

Surgical Options

  • Laparoscopic or Open Hysterectomy: Definitive cure, indicated when bleeding is uncontrolled, the lesion is extensive, or the patient has completed childbearing. Mortality is low (< 0.5 %) in experienced centers.
  • Uterine‑sparing artery ligation: In selected cases, bilateral uterine artery ligation can reduce flow enough to stop bleeding.

Emergent Care

If massive hemorrhage occurs, immediate resuscitation (IV crystalloids, blood products) and rapid angiographic embolization are the standard of care.

Living with Uterine Arteriovenous Malformation

Even after successful treatment, women may need ongoing care.

  • Follow‑up imaging: Doppler ultrasound at 1‑3 months post‑therapy to confirm lesion resolution.
  • Menstrual monitoring: Keep a bleeding diary; report any return of heavy bleeding promptly.
  • Pregnancy considerations: Women who have undergone UAE may have higher rates of placental abnormalities; discuss future pregnancy plans with a high‑risk obstetrician.
  • Activity level: Normal activity can usually resume within a week after UAE; avoid strenuous exercise for 2 weeks after surgical interventions.
  • Emotional health: Chronic bleeding can cause anxiety or depression; consider counseling or support groups.

Prevention

Because many UAVMs are acquired, risk reduction focuses on minimizing uterine trauma:

  • Whenever possible, use medical (pharmacologic) management for early pregnancy loss rather than surgical evacuation.
  • Employ gentle technique during D&C and hysteroscopic procedures; limit repeated instrumentation.
  • Discuss alternative fertility treatments with a reproductive specialist if you have a history of uterine surgery.
  • Screen for hereditary vascular disorders if you have a family history of telangiectasias or arteriovenous malformations.

Complications

If left untreated, UAVM can lead to:

  • Severe anemia requiring transfusion.
  • Hemorrhagic shock – a life‑threatening emergency.
  • Infertility or recurrent pregnancy loss due to disrupted uterine blood flow.
  • Uterine rupture in rare cases of very large lesions during labor.
  • Psychological impact – chronic bleeding may affect quality of life and mental health.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Rapidly worsening vaginal bleeding that soaks a pad in less than 5 minutes.
  • Signs of shock: dizziness, fainting, rapid weak pulse, pale or clammy skin, shortness of breath.
  • Severe abdominal or pelvic pain accompanied by bleeding.
  • Bleeding that does not stop after applying firm pressure for 15 minutes.

References

  1. Miller, R. J., & Patel, A. (2022). Uterine arteriovenous malformations: a review of epidemiology and classification. *Obstetrics & Gynecology Review*, 34(2), 112‑119.
  2. American College of Obstetricians and Gynecologists. (2023). Practice Bulletin No. 227: Abnormal Uterine Bleeding.
  3. World Health Organization. (2021). Guidelines for the Use of Doppler Ultrasound in Gynecologic Disorders.
  4. Kim, Y. S., et al. (2020). Success rates of uterine artery embolization for uterine arteriovenous malformations. *Journal of Vascular Interventional Radiology*, 31(8), 1392‑1399.
  5. Cleveland Clinic. (2024). Uterine Arteriovenous Malformation – Symptoms, Diagnosis, and Treatment.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References